Bibliography

Abrahamsson J, Pahlman M, Mellander L. Interleukin 6, but not tumour

necrosis factor-alpha, is a good predictor of severe infection in febrile

neutropenic and nonneutropenic children with malignancy. Acta Paediatr.

1997; 86(10):1059-64.

ADA (American Diabetes Association). Diagnosis and classification of

diabetes mellitus. Diabetes Care. 2005; 28: S37–S43.

ADA (American Diabetes Association). Diagnosis and classification of

diabetes mellitus. Diabetes Care. 2008; 31: 55–60.

Adamiec-Mroczek J, Oficjalska-Mlynczak J, Misiuk-HojloM Roles of

endothelin-1 and selected proinflammatory cytokines in the pathogenesis of

proliferative diabetic retinopathy: Analysis of vitreous samples. Cytokine.

2010; (49) 3: 269-74.

Adamiec-Mroczek J, Oficjalska-Młyńczak J. Assessment of selected adhesion

molecule and proinflammatory cytokine levels in the vitreous body of

patients with type 2 diabetes--role of the inflammatory-immune process in

the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp

Ophthalmol. 2008; 246(12):1665-70.

Ahima RS and Flier JS. Leptin. Annu.Rev.Physiol. 2000; 62:413-437.

Aiello LM, Am J Ophthalmol. 2003, 136:122.

152

Bibliography

Al-Dhar MHS and Jiffery EH. Increased adipose tissue expression of TNF-α

and insulin resistance in obese subjects with type-2 Diabetes. 2010; 5(2):30-

50.

Aldhahi W, and Osama Hamdy. Adipokines, Inflammation, and the Endotheli

um in Diabetes. Diabetes Reports. 2003; 3:293–298.

Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A.Inflamm

-atory process in type-2 diabetes: The role of cytokines. Ann N Y Acad Sci.

2006; 1084:89–117.

Al-Shatti T, Barr AE, Safadi F, Amin M, Barbe MF. Increase in pro-and anti -

inflammatory cytokines in median nerves in a rate model of repetitive

motion injury. J Neuro immunol. 2005; 167:13-22.

American Diabetes Association. Diabetes, June, 2005 vol 54.

American diabetes association. Diagnosis and classification of diabetes

mellitus. Diabetes care. 2005; 28:1537-452.

Anabela P, Rolo Carlos M, Palmeira. Diabetes and mitochondrial function:Role 

of hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology

2006; 212:167–178.

Bajaj M, Suraamornkul S, Pratipanawatr T. Pioglitazone reduces hepatic fat

content and augments splanchnic glucose uptake in patients with type 2

diabetes. Diabetes. 2003; 52: 1364–70.

153

Bibliography

Bastard J.P. Adipose tissue IL-6 content correlates with resistance to insulin

activation of glucose uptake both in vivo and in vitro. Journal of Clinical

Endocrinology and Metabolism. 2002; 87: 2084–2089.

Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainq

ue B. Elevated levels of IL6 are reduced in serum and subcutaneous adipose

tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000; 8:

3338.

Bastard JP, Maachi M, Tran Van Nhieu J, Jardel C, Bruckert E, Grimaldi A,

Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with

resistance to insulin activation of glucose uptake both in vivo and in vitro. J

Clin Endocrinol Metab. 2002; 87: 2084.

Bastard JP, Mustapha Maachi, Claire Lagathu, Min Ji Kim, Martine Caron.

Recent advances in the relationship between obesity, inflammation, and

insulin resistance Eur. Cytokine Netw. 2006; Vol. 17 4-12.

Baud L, Fouqueray B, Philippe C, Amram A. Tumor necrosis factor andα

mesangial cells. Kidney Int. 1992; 41:600–3.

Behl Y, Padmaja Krothapalli, Tesfahun Desta, Amanda DiPiazza, Sayon Roy,

and Dana T. Graves Diabetes-Enhanced Tumor Necrosis Factor-α Production

Promotes Apoptosis and the Loss of Retinal Microvascular Cells in Type 1

and Type 2 Models of Diabetic Retinopathy The American Journal of

Pathology. 5, May 2008. Vol. 172.

154

Bibliography

Bergman RN, Mittelman SD: Central role of the adipocytes in insulin resist-

ance. J Basic Clin Physiol Pharmacol. 1998, 9:205–221.

Bergman RN. Lilly lecture 1989. Toward physiological understanding of

glucose tolerance. Minimal-model approach, Diabetes 1989; 38: 1512–27.

Biswas NR, Das GK, Dubey AK. (Monoclonal antibodies in ophthalmology.

Nepal Med Coll J. 2010; 12(4):264-71.

Bluher M. Adipose tissue selective insulin receptor knockout protects again-

st obesity and obesity-related glucose intolerance. Dev. Cell. 2002; 3:25–36.

Boden G. Role of fatty acids in the pathogenesis of insulin resistance and

NIDDM. Diabetes. 1997; 46: 3–10.

Bogdan SZD, Katedrap BK. Molecular mechanisms of the damaging effect of

glucose on tissues. Diabetologia. 2006; 6, 5, 227–234.

Borst SE. The role of TNF-alpha in insulin resistance. Endocr.  2004;

23:177–182.

Bouzakri K, Zierath JR. MAP4K4 gene silencing in human skeletal muscle

prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem.

2007; 282:7783–7789.

Brosius FC. New insights into the mechanisms of fibrosis and sclerosis in

diabetic nephropathy. Review on Endocrinology and Metabolism Disorder

2008; 9:245-254.

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–820.

155

Bibliography

Brownlee M. Diabetes vol 54, june 2005.

Bruce CR and Dyck DJ. Cytokine regulation of skeletal muscle fatty acid

metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J

Physiol Endocrinol Metab. 2004; 287:616–621.

Bruun JM, Lihn AS, Verdich, Pedersen SB, Toubro S, Astrup P, Richelsen B.

Regulation of adiponectin by adipose tissue-derived cytokines; in vivo and

in vitro investigations in human. Am J. Physiol. Endocrinol. Metab. 2003;

285:527-533.

Buse JB, Polonsky KS, Burant CF. Type 2 Diabetes mellitus. In: Larsen PR,

Krokenberg HM, Melmed S, Polonsky KS. Williams Text Book of Buse

Endocrinology. Philadelphia: Saunders. 2003. Pp.1427–42.

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. -cell defi-β

cit and increased -cell apoptosis in humans with type 2 diabetes. Diabetesβ

2003; 52: 102-10.

Cao YL, Wang YX, Wang DF, Meng X, Zhang J. Correlation between TNF-

alpha protein and plasma PAI-1 in obesity subjects. International Journal of

cardiology.  2008; 128:399–405.

Cao YC, Hu X, Meng D, Wang DF and Zhang J. Expression of TNF- proteinα

in omental and subcutaneous adipose tissue in obesity. Diabetes research

and Clinical Practice. 2008; 79: 214-216.

156

Bibliography

Carbo N, Costelli P, Tessitore L, Bag GJ, Lopez Soriano FJ, Baccino FM, Argil-

es JM. Anti-tumour necrosis factor-alpha treatment interferes with changes

in lipid metabolism in a cachectic tumor model. Clin Sci. 1994; 87:349-355.

Carey AL. Interleukin-6 and tumor necrosis factor-alpha are not increased

in patients with Type-2 diabetes: evidence that plasma interleukin-6 is

related to fat mass and not insulin responsiveness. Diabetologia. 2004; 47:

1029–1037.

Carmen Mora Fernandez and Juan F. Navarro Gonzalez. The Role of Inflamm

atory Cytokines in Diabetic Nephropathy. Journal of American Society of

Nephrology. 2008; 19: 433–442.

Centre for disease Control and Prevention. National Diabetes Fact Sheet.

United States, 2005.

Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of

weight loss on renal function in patients with severe obesity. Journal of

American Society of Nephrology. 2003; 14:1480-1486.

Chan MH, Carey AL, Watt MJ, Febbraio MA. Cytokines gene expression in

human skeletal muscle during concentric contraction: evidence that IL-8,

like IL-6, is influenced by glycogen availability. Am J Physiol. Regulatory

integrative Comp. Physiol. 2004; 287:R322-R327.

157

Bibliography

Chen S, Cohen MP, Lautenslager GT, Shearman CW, Ziyadeh FN. Glycated

albumin stimulates TGF-beta 1 production and protein kinase C activity in

glomerular endothelial cells. Kidney International. 2001; 59: 673–681.

Cheung AT, Ree D, Koll JK, Fuselier J, Coy DH, Bryerash M. An in vivo model

for elucidation of the mechanism of tumor necrosis factor-alpha (TNF- )α

induced insulin resistance. Evidence for a differential regulation of insulin

signaling by TNF-α. Endocrinology. 1998; 139:4928-4935.

Cornelius P, Marlowe M, Lee MD, Pekala PH. The growth factor-like effects

of tumor necrosis factor-alpha. Stimulation of glucose transport activity and

induction of glucose transporter and immediate early gene expression in

3T-L1preadipocytes. J BioI Chem. 1991; 265: 20506-20516.

Coulon J, Willems D, Dorchy H. Increase in C-reactive protein plasma levels

during diabetes in infants and young adults. Presse Med. 2005; 34(2 Pt

1):89-93.

Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular

disease: pathophysiology, clinical consequences, and medical therapy: Part I.

Circulation. 2003; 108:1527-1532.

Crispin JC, Alcocer-Varela J. Rheumatologic manifestations of diabetes mellitus. Am J Med. 2003; 114: 753-757.

158

Bibliography

Dace DS, Apte RS. Effect of senescence on macrophage polarization and

angiogenesis. Rejuvenation Res. 2008; 11 (1):177-85.

Dalla Vestra M, Mussap M, Gallina P. Acute phase markers of inflammation

and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol

2005; 16:S78-S82.

Danforth E Jr. Failure of adipocytes differentiation causes type-2 diabetes

mellitus? Nat Genet. 2000; 26: 13.

Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell.  2000;

103:239–252.

Del Aguila LF, Claffey KP, Kirwan JP. Tumour necrosis factor Impairs insulin 

signaling and insulin stimulation of glucose uptake in C2C12 Muscle cells. A

m J Physiol Endocrinol Metab. 1999; 276: 849-855.

Del Aguila LF, Krishnan RK, Ulbrecht JS, Farrell PA, Correll PH, Lang CH,

Zierath JR, Kirwan JP: Muscle damage impairs insulin stimulation of IRS-1, PI

3-kinase, and Akt-kinase in human skeletal muscle. Am J Physiol Endocrinol

Metab.  2000; 279:E206–E212.

Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, mon

ocyte adhesion, and tumor necrosis factor alpha production in NIDDM pati-

ents after gliclazide treatment. Diabetes Care. 1998; 21:487-493.

159

Bibliography

Devaraj S, Senthil K, Venugopal, Uma singh, and Ishwarlal jialal.

Hyperglycemia induces monocytic release of IL-6 via induction of protein

kinase C- and- Diabetes vol, 54, January 2005.α β

Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in noninsulin-

dependent diabetes mellitus. N Engl J Med. 1992; 327: 707–13.

DoerrIer W, Feingold KR, Grunfeld C Cytokines induce catabolic effects in

cultured adipocytes by multiple mechanisms. Cytokine. 1994; 6:478-484

Doganay S, Evereklioglu C, Turkoz ERH, Sevinc A, Mehmet N, Savli H.

(Comparison of serum NO, TNF-α, IL-1 , sIL-2R, IL-6 and IL-8 levels withβ

grades of retinopathy in patients with diabetes mellitus.  2002; 16:163-70.

Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J,

Brownlee M: Hyperglycemia-induced mitochondrial superoxide over

production activates the Hexosamine pathway and induces plasminogen

activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl

Acad Sci USA 97. 2000; 12222–12226.

Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D et al. SOCS-3 is an

insulin-induced negative regulator of insulin signalling. J Biol Chem. 2000;

275:15985–15991.

160

Bibliography

Engerman RL, Kern TS, Larson ME: Nerve conduction and aldose reductase

inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia. 

1994; 37:141–144.

Eschwege E, Simon D, Balkau B. The growing burden of diabetes in the world

population. IDF bulletin. 1997; 42:14-9.

Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical

Pathophysiology of maturity-onset diabetes of the young. N Engl J Med.

2001; 345:971–80.

Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6

is a novel factor mediating glucose homeostasis during skeletal muscle

contraction. Diabetes. 2004; 53:1643–1648.

Feingold KR , Marshall M ,Gulli R, Moser AH , Grunfeld C. Effect of endotoxin

and cytokines on lipoprotein lipase activity in mice. Arterioscler. Thromb.

1994; 14: 1866-1872.

Feingold KR and Grunfeld C. Role of cytokines in inducing hyperlipidemia.

Diabetes. 1992; 41(2):97-101.

Feingold KR, Doerrler W, Dinarello CA, Fiers W, Grunfeld C Stimulation of

lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and

interferons is blocked by inhibition of prostaglandin synthesis.

Endocrinology. 1992; 130:10-16.

161

Bibliography

Fernandez-Real JM, & J. C. Pickup Innate immunity, insulin resistance and

type 2 diabetes. Published online: 30 November 2011.

Fernandez- Real JM, Broch M, Vendrell J, Gutierrez C, Casamitajana R,

Pugeat M, Richart C, Ricart W: Interleukin-6 gene polymorphism and

insulin sensitivity. Diabetes. 2000; 49:517-520.

Festa AD, Agostino R, Howard G, et al.: Chronic subclinical inflammation as

part of the insulin resistance syndrome: the Insulin Resistance

Atherosclerosis Study (IRAS).Circulation. 2000; 101:42–47.

Frank B, Hu, James B. Meigs, Tricia Y. Li, Nader Rifai, and Jo Ann E. Manson

Inflammatory Markers and risk of developing type-2 diabetes in women. .

Diabetes, VOL, 52, March 2004.

Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose

tissues of obese subjects release interleukin-6: depot difference and

regulation by glucocorticoid. J Clin Endocrinol Metab. 1998; 83: 847.

Friedwald WT, Levy RI. Estimation of the concentration of Low density

lipoprotein Cholesterol I Plasma, without use of preparative ultracentrifuge.

Clin Chem. 1972; 18: 499-502

Funk M, Schmidinger G, Maar N, Bolz M, Benesch T, Zlabinger GJ, Schmidt-

Erfurth UM. Angiogenic and inflammatory markers in the intraocular fluid

162

Bibliography

of eyes with diabetic macular edema and influence of therapy with

bevacizumab. Retina. 2010; 30(9):1412-9.

Furukawa S, et al. 2004. Increased oxidative stress in obesity and its impact

on metabolic syndrome. J. Clin. Invest. 2004; 114:1752–1761.

Gao Z, et al. Serine phosphorylation of insulin receptor substrate 1 by

inhibitor kappa B kinase complex. J. Biol. Chem. 2002; 277:48115–48121.

Gerich J. The genetic basis of type 2 diabetes mellitus: impaired insulin

secretion versus impaired insulin sensitivity. Endocr Rev. 1998; 19:491-

503.

Gardena I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent

hyperglycemia induced formation of intracellular advanced glycation end

products in bovine endothelial cells. J. Clin. Invest. 1996; 97: 1422–1428.

Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse

events after intravitreal infliximab (Remicade). Retina. 2010; 30(1):71-80.

Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial

dysfunction, and imbalanced coagulation in development of diabetes and its

complications. J Clin Endocrinol Metab. 2009; 94:3171–82.

Green A, Dobias SB, Walters DJ, Brasier AR. Tumor necrosis factor increases

the rate of lipolysis in primary cultures of adipocytes without altering levels

of hormonesensitive lipase. Endocrinology 1994; 134:2581-2588.

163

Bibliography

Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, Londos C.

Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein

associated with the periphery of the lipid storage droplets. J Biol Chem.

1991; 266:11341-11346.

Greenberg AS, Nordan RP, McIntosh J, Calvo JP, Scow RO, Jablons D.

Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in

vivo and in 3T3–L1 adipocytes: a possible role for interleukin 6 in cancer

cachexia. Cancer Res. 1992; 52:4113–4116.

Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin

resistance and -cell function: potential role of adipocyte-derived cytokinesβ

in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002; 32 (Suppl 3):

24-34.

Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content

correlates with resistance to insulin activation of glucose uptake both in

vivo and in vitro. J Clin Endocrinol Metab. 2002; 87:2084.

Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an

independent serum marker for proliferative retinopathy in type 1 diabetic

patients. J DiabetesComplications. 2008; 22(5):309-16.

Hardri KE, Courtalon A, Gauthereau X, Chambaut-Guerin AM, Pairault J, Feve

B Differential regulation by tumor necrosis factor-alpha of beta1-, beta2-,

164

Bibliography

and beta3adrenoreceptor gene expression in 3T3-F442A adipocytes. J Biol

Chem. 1997; 272:24514-24521.

Hales CN, Ozanne SE. Fetal and early postnatal growth Restriction lead to

diabetes, the metabolic syndrome and renal failure. Diabetologia. 2003;

46:1013-9.

Hatada EN, Krappmann, D, and Scheidereit C. NF-kappa B and the innate

immune response. Curr. Opin. Immunol. 2000; 12:52–58.

Hauner H, Petruschke T, Russ M, Eckel J Effects of tumour necrosis factor

alpha on glucose transport and lipid metabolism of newly-differentiated

human fat cells in cell culture. Diabetologia. 1995; 38:764-771.

Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and

structural changes in the kidney in the early stages of obesity. Journal of

American Society of Nephrology. 2001.

Hirano T, Akira S, Taga T and Kishimoto T. Biological and clinical aspect of

interleukin 6. Immunol Today. 1990; 11:443–449.

Hirosumi J, et al. A central role for JNK in obesity and insulin resistance.

Nature. . 2002; 420:333–336.

Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine

kinase activity of the insulin receptor in obesity-diabetes. Central role of

tumor necrosis factor-alpha. J Clin Invest. 1994; 94:1543-1549.

165

Bibliography

Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumour necrosis

factor alpha inhibits signalling from the insulin receptor, Proc. Natl. Acad.

Sci. USA. 1994; 94: 1304-1309.

Hotamisligil GS, Murry DL, Choy LN, Spiegelman B. TNF inhibits signallingα

from insulin receptor. Proc Natl Acad Sci USA. 1994; 91:4854-4858.

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-

1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-

alpha- and obesity-induced insulin resistance. Science. 1996; 271:665–668.

Hotamisligil GS, Shargill NS, Spiegelman BM. adipose expression of tumer

necrosis factor-alpha: direct role in obesity-linked insulin resistance science

1993; 259:87.

Hotamisligil GS. IRS-1-mediated inhibition of insulin receptor tyrosine

kinase activity in TNF-alpha- and obesity-induced insulin resistance.

Science. 1996; 271:665–668.

Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of

diabetic nephropathy. Kidney Int. 2001; 59:702–709.

Howard JK, et al. Enhanced leptin sensitivity and attenuation of diet-

induced obesity in mice with haply insufficiency of Socs3. Nat. Med. 2004;

10:734–738.

166

Bibliography

Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. Signaling

through the hematopoietic cytokine receptors. Annu Rev Immunol. 1995;

13: 369.

International Diabetes Federation, 2000.

Jatla jyothi swaroop, Duggirala Rajarajeswari & JN, Naidu. Association of

TNF- with insulin resistance in type-2 diabetes mellitus. Indian J Med Resα

135, January 2012, pp 127-130.

Jaattela M. Biologic activities and mechanisms of action of tumor necrosis

factor-a/cachectin. Laboratory Investigation. 1991; 64:724–42.

Jager J, Gremeaux T, Cormont M,  Marchand-Brustel Y, and Tanti JF.

Interleukin-1beta-induced insulin resistance in adipocytes through down-

regulation of insulin receptor substrate-1 expression. Endocrinology.

2007; 148:241–251.

Jaswinder K. Sethi and Gokhan S. Hotamisligil, Article No. scdb. 1999; 0273.

Joachim spranger, Anja Kroke, Mattias Mohlig, Kurt Hoffmann, Manuela M,

Bergmann, Michael Ristow, Heiner Boeing and Andereas F.H.Pfeiffer.

Inflammatory cytokine and the risk to develop type-2 diabetes. Diabetes,

VOL, 52, March 2003.

Joseph J. Senn, Peter J. Klover, Irena A. Nowak, and Robert A. Mooney.

Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes. Diabetes

2002; 51:3391–3399.

167

Bibliography

Joshi SV, Tambwekar SR, Khadalia K, Dhar HL, Role of Inflammatory Marker

Interleukin-6 (IL-6) and Insulin in Diabetes and Diabetic Neuropathy.

Bombay Hospital Journal. 2008; Vol. 50, No. 3.

Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S,

Adamis AP. Non steroidal anti-inflammatory drugs prevent early diabetic

retinopathy via TNF-alpha suppression. FASEB J. 2002; 16(3):438-40.

Juan F. Navarro and Carmen Mora Role of inflammation in diabetic

complications Nephrol Dial Transplant. 2005; 20: 2601–2604.

Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase:

ancient energy gauge provides clues to modern understanding of metabolism.

Cell Metab. 2005; 1:15-25.

Kahn SE. The relative contributions of insulin resistance and beta-cell

dysfunction to the Pathophysiology of Type 2 diabetes. Diabetologia. 2003;

46: 3-19.

Kamimura D, Ishihara K & Hirano T. IL-6 signal transduction and its

physiological roles: the signal orchestration model. Review of Physiology,

Biochemistry and Pharmacology. 2003; 149: 1–38.

Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y, Ito S,

Okumura T: Interleukin 1β and interleukin 6, but not tumor necrosis Factor-

α, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes.

Herpetology. 1998; 27:1296–1303.

168

Bibliography

Karin M, Delhase M.The I kappa B kinase (IKK) and NF-kappa B: key elements

of proinflammatory signalling. Semi Immunol. 2000; 12: 85–98.

Katarzyna Zorena, Dorota Raczynska, and Krystyna RaczyńskA. Immunologi

cal Risk Factors for the Development and Progression of Diabetic

Retinopathy. 2012; (Ed.), ISBN: 978-953-51-0044-7.

Katherine Esposito, Francesco Nappo, Raffaele Marfella Giovanni Giugliano,

Myriam Ciotola, Lisa Quagliaro, Antonio Ceriello and Dario Giugliano.

Inflammatory Cytokine Concentrations Are Acutely Increased by

Hyperglycemia in Humans. Circulation. 2002; 106:2067-2072.

Kathryn E. Wellen and Gokhan S. Hotamisligil, Inflammation, stress, and

diabetes: J. Clin. Invest. 2005; 115:1111–1119.

Kawakami M, Murase T, Ogawa H, Ishibashi S, Mori N, Takaku F, Shibata S

Human recombinant TNF suppresses lipoprotein lipase activity and

stimulates lipolysis in 3T3-L1 cells. J Biochem. 1987; 101:331-338.

Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J,

Saha AK, Pedersen BK, Ruderman NB. AMPK activity is diminished in tissues

of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun.

2004; 320:449–454.

Kern PA Recombinant human tumor necrosis factor does not inhibit

lipoprotein lipase in primary cultures of isolated human adipocytes. J Lipid

Res. 1988; 29:909-914.

169

Bibliography

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor

necrosis factor and interleukin-6 expression in human obesity and insulin

resistance. Am J Physiol Endocrinol Metab. 2001; 280:E745–E751.

Kim HJ, Higashimori T, Park SY, Choi H, Dong j, Kim yj, Noh HL , Cho YR

Cline G ,Kim YB , Kim JK. Differential effects of interleukin-6 and -10 on

skeletal muscle and liver insulin action in vivo. Diabetes. 2004; 53:1060-

1067.

Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycation

end products stimulate collagen mRNA synthesis in mesangial cells

mediated by protein kinase C and transforming growth factor-beta. Journal

of Laboratory Clinical Medicine. 2001; 138: 59–68.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025:

prevalence, numerical estimates, and projections. Diabetes Care. 1998;

21:1414–31.

King GL, Role of inflammatory cytokines in Diabetes, J Periodontal. 2008;

79:1527-1534.

Kirwan J.P, Raj K, Krishnan, James A, Weaver, Luis F, Del Aguila and William

J, Evans. Human aging is associated with altered TNF-alpha production

during hyperglycemia and hyperinsulinemia. AmJ physiol Endocrinol

metab. 2001; 281:E1137-E1143

170

Bibliography

Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to

interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003;

52:2784– 2789.

Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory

cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the

development of diabetic retinopathy. Folia Med. 2011; 53(2):44-50.

Kolm-Litty V, Sauer U, Nerlich A, and Lehmann R, Schleicher ED: High

glucose-induced transforming growth factor beta1 production is mediated

by the hexosamine pathway in porcine glomerular mesangial cells. J Clin

Invest. 1998; 101:160–169.

Kowluru RA, Chan PS. Exp Diabetes Res. 2007. Aiello LM Am J Ophthalmol. 

2003; 136: 122.

Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL: Characterization of

protein kinase C beta isform activation on the gene expression of

transforming growth factor-beta, extracellular matrix components, and

prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997; 100:115–

126.

Koya D, King GL: Protein kinase C activation and the development of

diabetic complications. Diabetes. 1998; 47:859–866.

Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and Diabetes. The Good,

the Bad, or the Indifferent? Diabetes. 2005; 54 (2):114–124.

171

Bibliography

Krogh-Madsen R, Peter Plomgaard, Pernille Keller, Charlotte Keller, Bête

Klarlund Pedersen. Insulin stimulates interleukin-6 and tumour necrosis

factor-alpha gene expression in human subcutaneous adipose tissue. Am J

Physiol Endocrinol Metab. 2003; 10.1152.

Kroder G, Bossenmaier B, Kellerer M, Capp E, Stoyanov B, Muhlhofer A,

Berti L, Horikoshi H, Ullrich A, Haring H. Tumor necrosis factor-alpha- and

hyperglycemia-induced insulin resistance. Evidence for different

mechanisms and different effects on insulin signaling. J Clin Invest.  1996;

97: 1471.

Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic

Interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin

resistance in adipocyte: Prevention by Rosiglitazone. Biochem Biophys Res

Com. 2003; 311: 372.

Lang CH, Silvis C, Deshpande N, Nystrom G, Frost RA. Endotoxin stimulates in

vivo expression of inflammatory cytokines tumor necrosis factor alpha,

interleukin-1β, -6, and high-mobility-group protein-1 in skeletal muscle.

Shock. 2003; 19: 538–546.

Lee AY, Chung SS: Contributions of polyol pathway to oxidative stress in

diabetic cataract. FASEB J, 1999; 13:23–30.

172

Bibliography

Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine

profile of peripheral blood in type 2 diabetes mellitus patients with diabetic

retinopathy. Ann Clin Lab Sci. 2008; 38(4):361-7.

Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA Peroxisome

proliferator-activated receptors alpha and gamma are activated by

indomethacin and other non steroidal anti-in flammatory drugs. J Biol

Chem. 1997; 272:3406-3410.

Limb G, Hollifield R, Webster L, Charteris D, Chignell A. Soluble TNF-

receptors in vitreoretinal proliferati-ve disease. Invest Opthalmol Vis Sci.

2001; 142, 1586-1591.

Lin Y. The hyperglycemia-induced inflammatory response in adipocytes: the

role of reactive oxygen species. J. Biol. Chem. 2005; 280:4617–4626.

Liu Y, Freedman BI. Genetics of progressive renal failure in diabetic kidney

disease. Kidney International.  2005; 94-97.

Liu S, Tinker L, Song Yiqing, Rifai N, Bonds DE, cook NR, Heiss G, Howard BV,

Hotamisligi GS, HU FB, Kuller LH, Manson JE. A prospective study of

inflammatory cytokines and diabetes mellitus in a multiethnic cohort of

postmenopausal women. Arch Intern Med. 2007; 167(15): 1676-1685.

173

Bibliography

Lopes AA. End-stage renal disease due to diabetes in racial/ethnic

minorities and disadvantaged populations. Review Ethn Dis. 2009; 19:S1

47–51.

Lopezsoriano J, Llovera M, Carbo N, Garciamartinez C, Lopezsoriano FJ,

Argiles JM. Lipid metabolism in tumour-bearing mice-studies with knockout

mice for tumour necrosis factor receptor 1 protein. Mol Cell Endocrinol

1997; 132:93-99.

Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in human

splanchnic and adipose tissue. J Physiol. 2002; 543:379 –386.

Lopezsoriano FJ, Bagby GJ, Williamson DH, Argiles JM. Anti-TNF treatment

does not reverse the abnormalities in Lipid metabolism of the obese Zucker

rat. Am J Physiol. 1997; 35:E656-E660.

Maassen JA, Hart LM, Van Essen E, et al. Mitochondrial diabetes: molecular

mechanisms and clinical presentation. Diabetes. 2004; 53 (suppl 1): S103–

09.

Machann J, Haring H, Schick F, Stumvoll M. Intramyocellular lipids and

insulin resistance. Diabetes Obes Metab. 2004; 6: 239–48.

Mahato RV, Gyawali P, Raut PP, Regmi P, Singh KP, Pandeya DJ, Gyawali P.

Association between glyacemic control and serum lipid profile in type 2

diabetic patients: glycated haemoglobein as a dual biomarker. Biomedical

Research. 2011; 22(3): 375-380.

174

Bibliography

Mariano F, Bussolati B, Piccoli G, Camussi B. Renal vascular effects of

cytokines. Blood Purification. 1997; 15:262–272.

Masakazu H, Daisuke K, Motohide ISONO, and Ryuichi K. Overview of

Glucose Signaling in Mesangial Cells in Diabetic Nephropathy. American

Society of Nephrology. 2003; 14: 1374–1382.

Mavridis G, Souliou E, Diza, Symeonidis E, Pastore F, Vassiliou AM,

Karamitsos D.  Inflammatory cytokines in insulin- treated patients with type

2 diabetes. Nutr.Metab. Cardiovasc. Dis.  2007; 17:409-414.

McCarthy ET, Sharma R, Sharma M. TNF-alpha increases albumin permeability

of isolated rat glomeruli through the generation of superoxide Journal  of

American Society of Nephrolog .  1998; 9:433–438.

Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol.

2001; 1:135–145.

Memon RA, Feingold KR, Moser AH, Fuller J, Grunfeld C Regulation of fatty

acid transport protein and fatty acid translocase mRNA levels by endotoxin

and cytokines. Am J Physiol.  1998; 37:E210-E217.

Memon RA, Fuller J, Moser AH, Smith PJ, Feingold KR, Grunfeld C in vivo

regulation of acyl-CoA synthetase mRNA and activity by endotoxinand

cytokines. Am J Physiol. 1998; 38:E64-E72.

175

Bibliography

Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal

renal and hepatic glucose metabolism in type 2diabetes mellitus. J Clin

Invest. 1998; 102: 619-24.

Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM. TNF-alpha-

induced insulin resistance in vivo and its prevention by troglitazone.

Diabetes. 1997; 46:1678–1683.

Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T,Kibata M.Relationship

between serum necrosis factor-alpha and insulin resistance in obese men

with type-2 diabetes mellitus Diabetes Res Clin Pract. 2001; 52:119-123.

Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S,

Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not

tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metabo. 1997;

82:4196–4200.

Mohammed Qatanani and Mitchell A. Lazar. Mechanisms of obesity-associated

insulin resistance: many choices on the menu. Genes Dev. 2007; 21: 1443-

1455.

Montague CT, Rahilly S. The perils of portliness. Causes and consequences of

visceral adiposity. Diabetes. 2000; 49: 883-8.

Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto

RW. Suppressors of cytokine signaling-1 and -6 associate with and inhibit

176

Bibliography

the insulin receptor. A potential mechanism for cytokine-mediated insulin

resistance. J Biol Chem.  2001; 276: 25889.

Mori H, et al. Socs3 deficiency in the brain elevates leptin sensitivity and

confers resistance to diet-induced obesity. Nat. Med. 2004; 10:739–743.

Morrish MF. Insulin receptor signaling and regulation in textbook of

Diabetes. 3rd ed. PicupJC, William G. U.K, Black well. 2003; 14. 1-14.17.

Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of

death in the WHO multinational study of vascular disease in diabetes.

Diabetologia. 2001; 44:S14–S21.

Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B,

Giani G, Illig T, Thorand B, Kolb H. Impaired glucose tolerance is associated

with increased serum concentrations of interleukin 6 and co-regulated acute-

phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002;

45:805–812.

Nakatani Y. Involvement of endoplasmic reticulum stress in insulin resistance

and diabetes. J. Biol. Chem. 2005; 280:847–851

Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr

Drug Inflamm Allergy 2005.

Nandi D, Mishra MK, Basu A, Bishayi BProtevtive effects of interleukin-6 in

lipopolisacharide (LPS)-induced experimental endotoxemia are linked to

177

Bibliography

alteration in hepatic anti-oxidant enzymes and endogenous cytokines.

Immuno biology. 2010; 215:443-451.

Navarro-Gonzalez JF, Mora Fernandez C. The role of inflammatory cytokines

in diabetic nephropathy. Journal of American Society of Nephrology. 2008;

19:433–442.

Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D,

Shaw A. Cloning and expression of a cell surface receptor for advanced

glycosylation end products of proteins. Journal of Biological Chemistry

1992; 267:14998 –15004.

Nichols GA, Glauber HS, Brown JB. Type-2 diabetes: incremental medical

care costs during the 8 years preceding diagnosis. Diabetes Care. 2000;

23:1654–59.

Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of

interleukin-6 and vascular endothelial growth factor in macular edema with

central retinal vein occlusion. Ophthalmology. 2009; 116(1):87-93.

Noronha IL, Niemir Z, Stein H, Waldherr R. Cytokines and growth factors in

renal disease. Nephrology Dialysis and Transplantation. 1995 ; 10:775– 786

Oh IK, Kim SW, Oh J, Lee TS, Huh K. Inflammatory and angiogenic factors in

the aqueous humor and the relationship to diabetic retinopathy. Curr Eye

Res. 2010; 35(12):1116-27.

178

Bibliography

Ohga S, Shikata K, Yozai K. Thiazolidinedione ameliorates renal injury in

experimental diabetic rats through anti-inflammatory effects mediated by

inhibition of NF-kappa activation. American Journal of Renal Physiology.

2007; 292:F1141–F1150.

Opera EC. Oxidative stress, micronutrients, diabetes mellitus and its

complications. J R Soc Health. 2002; 122:28– 34.

Orasanu G, Plutzky J. The Pathologic Continuum of Diabetic Vascular

Disease. Journal of the American College of Cardiology. 2009; Vol 53.

Ortiz A, Bustos C, Alcazar A, Lopez-Armada M, Plaza J, Gonzalez E.

Involvement of tumor necrosis factor-a in the pathogenesis of experimental

and human glomerulonephritis. Advances in nephrology. 1995; 53–77.

Ostendorf T, Burg M, Floege J. Cytokines and glomerular injury. Kidney and

Blood Pressure Research. 1996; 19:281–289.

Ozawa, K., et al. The endoplasmic reticulum chaperone improves insulin

resistance in type 2 diabetes. Diabetes. 2005; 54:657–663.

Ozcan, U, et al. Endoplasmic reticulum stress links obesity, insulin action,

and type II diabetes. Science. 2004; 306:457–461.

Pamir N, McMillen TS, Kaiyala KJ, Schwartz MW, LeBoeuf RC. Receptors for

tumor necrosis factor-alpha play a protective role against obesity and alter

adipose tissue macrophage status. Endocrinology. 2009; 50:4124–4134.

179

Bibliography

Pape ME, Kim KH Effect of tumor necrosis factor on acetyl-coenzyme A

carboxylase gene expression and preadipocyte differentiation. Mol

Endocrinol. 1988; 2:395-403.

Papanicolaou DA, Vgontzas AN. Interleukin-6: the endocrine cytokine. J Clin

Endocrinol Metab. 2000; 85:1331–1333.

Parving H. Diabetic nephropathy: Prevention and treatment. Kidney Int.

2001; 60:2041–2055.

Pedersen BK, Akerstrom TCA, Nielsen AR, Fischer CP. Role of myokines in

exercise and metabolism. J Appl Physiol. 2007; 35:1295-1297.

Pedersen BK, Steensberg A, Schjerling P. Mouse-derived interleukin-6:

possible biological effects. J Physiol.  2001; 526:329-337.

Pedersen M, Bruunsgaard H, Weis N, Hendel HW et al. Circulating levels of

TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy

elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev.

2003; 124:495–502.

Perreault M, and Marette A. Targeted disruption of inducible nitric oxide

synthase protects against obesity-linked insulin resistance in muscle. Nat.

Med. 2001; 7:1138–1143.

Perseghin G, and Shulman G.I. Cellular mechanism of insulin resistance:

potential links with inflammation. Int. J. Obes. Relat. Metab. Disord. 2003;

27(Suppl. 3):S6–S11.

180

Bibliography

Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL et al. Acute

IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in

tissue culture in vitro. Am J Physiol Endocrinol Metab. 2005; 288:155–162.

Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate

immune system: association of acute-phase reactants and interleukin-6 with

metabolic syndrome X. Diabetologia. 1997; 40:1286-1292.

Pickup JC, Chusney GC, Thomas S. M, Burt D. Plasma interleukin-6, tumor

necrosis factor and blood cytokine production in type 2 diabetes. Life Sciα

2000; 67:291–300.

Pickup JC and Crook MA.Is type II diabetes mellitus a disease of the innate

immune system Diabetologia. 1998; 41:1241-1248.

Pickup JC. Inflammation and activated innate immunity in the pathogenesis of

type-2 Diabetes. Diabetes Care. 2004; 27:813-823.

Pingle SC, Mishra S, Marcuzzi A, Bhat SG, Sekino Y, Rybak LP, Ramkumar V.

Osmotic diuretics induce adenosine A1 receptor expression and protect

renal proximal tubular epithelial cells against cisplatin-mediated apoptosis.

Journal of Biology Chemistry. 2004; 279:43157– 43167.

Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR,

Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin

resistance in healthy human subjects via inhibition of Akt substrate 160

phosphorylation. Diabetes. 2005; 54:2939–2945.

181

Bibliography

Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH et al. Associations

between insulin resistance and TNF- in plasma , skeletal muscle andα

adipose tissue in humans with and without type II diabetes. Diabetologia

2007; 50:2562-2571.

Polonsky KS. The beta-cell in diabetes: from molecular genetics to clinical

research. Diabetes. 1995; 44: 705-17.

Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at

diagnosis (latent autoimmune diabetes of the adult): definition,

characterization, and potential prevention. Diabetes Care. 2001; 24:1460–

67.

Pradhan AD, Manson JE, Rifai N, Burin JE, Ridker PM: C - reactive protein,

interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;

286:327–334.

Rai KB, Pattabiraman TN. Glycosylated haemoglobin levels in iron deficiency

anaemia. Indian J Med Res. 1986; 83: 234-6.

Ram Vinod Mahato, Prajwal Gyawali, Pramod Psd. Raut, Prashant Regmi,

Khelanand Psd. Singh, Dipendra Raj Pandeya, Prabin Gyawali.Association

between glycemic control and serum lipid profile in type- 2 diabetic patients:

Glycated haemoglobin as a dual biomarker. Biomedical Research. 2011; 22

(3): 375-380.

182

Bibliography

Ramsay TG Fat cells. Endocrinol Metab Clin N Am. 1996; 25:847-870.

Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and

failure of fat cell proliferation result in ectopic fat storage, insulin

resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci. 2002; 967: 363-

78.

Reaven GM. The fourth Musketeer-from Alexandre Dumas to Claude

Bernard. Diabetologia. 1995; 38: 3-13.

Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of

plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with

NIDDM. Diabetes. 1988; 37: 1020-1024.

Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, Laville

M, Vidal H. SOCS (Suppressor Of Cytokine Signaling)-3 Expression and

Insulin Resistance in Skeletal Muscle of Obese and Type 2 Diabetic Patients.

Diabetes. 2004; 53: 2232.

Rivero A, Mora C, Muros M, Garcia J, Herrera H and Navarro-Gonzalez J.N.

Pathogenic perspectives for the role of inflammation in diabetic

nephropathy. Clinical Science. 2009; 116:479–492

Rohilla A, Rupesh Kumar, Seema Rohilla, Ashok Kushnoor. Diabetic Retinop

athy: Origin and Complications. Euros. Exp. Bio. 2012, 2(1):88-94.

183

Bibliography

Romero Aroca P, Mendez-Marin I, Baget-Bernaldiz M, Fernendez-Ballart J,

Santos-Blanco E. Review of the relationship between renal and retinal

microangiopathy in diabetes mellitus patients. Current Diabetes Review.

2010; 6:88–101.

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;

340:115–126.

Rossing P. Diabetic nephropathy: Worldwide epidemic and effects of

current treatment on natural history. Curr Diab Rep. 2006; 6:479–483.

Royall J, Berkow RL, Beckman JS, Cunningham MK, Matalon S and Freeman

BA. Tumor necrosis factor and interleukin 1 increase vascular endothelial

permeability. American Journal of Physiology. 1989; 257: L339–L410.

Rui, L. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated

degradation of IRS1 and IRS2. J. Biol. Chem. 2002; 277:42394–42398.

Ruminy P, Gangneux C, Claeyssens S, Scott M, Daveau M, Salier JP. Gene

transcription in hepatocytes during the acute phase of a systemic

inflammation: from transcription factors to target organ. Inflamm Res.

2001; 50:383-390.

Saltiel, AR, and Pessin, JE. Insulin signalling pathways in time and space.

Trends Cell Biol. 2002; 12:65–71.

184

Bibliography

Sanchez RN, Chan CK, Garg S, Kwong JM, Wong MJ, Sadun AA,

LamTT. Interleukin-6 in retinal ischemia reperfusion injury in rats. Invest

Ophtalmol Vis Sci. 2003; 44:4006-4011.

Sappington RM, Calkins DJ Pressure-induced regulation of IL-6 in retinal

glial cells,involvement of the ubiquitin/proteasome pathway and NFkappaB.

Invest Ophthalmol Vis Sci. 2006; 47(9):3860-9.

Sayesk PP, Kudlow JE: Glucose metabolism to glucosamine is necessary for

glucose stimulation of transforming growth factor-alpha gene transcription.

J Biol Chem. 1996; 271:15237–15243.

Scheen AJ, Lefebvre PJ. Assessment of insulin resistance in vivo. Application

to the study of type 2 diabetes. Horm Res. 1992; 38:19-27.

Scheen AJ, Lefebvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J,

Puls W, eds. Handbook of Experimental Pharmacology, Oral Antidiabetics.

Berlin: Springer Verlag. 1996; 7-42.

Scheen AJ, Paquot N, Letiexhe MR, Paolisso G, Castillo MJ, Lefèbvre PJ.

Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp

studies. Int J Obesity. 1995; 19 (Suppl 3): S14-S20.

Scheen AJ. Insulin resistance syndrome and atherosclerotic cardiovascular

disease. Acta Clin Belg. 1996; 51: 65-9.

Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD Brett J,

Stern D. Advanced glycation end products interacting with their endothelial

185

Bibliography

receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1)

in cultured human endothelial cells and in mice: a potential mechanism for

the accelerated vasculopathy of diabetes. Journal of Clinical Investigation.

1995; 96:1395–1403.

Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in

skeletal muscle. Ann. N. Y. Acad. Sci. 2002; 967:146-157.

Scott JA, King GL. Oxidative stress and antioxidant treatment in diabetes. Ann

N Y Acad Sci. 2004; 1031: 204-213.

Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular

insulin resistance in hepatocytes. Diabetes. 2002; 51:3391–3399.

Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in

the liver is associated with defects in insulin suppression of glucose

production and serum free fatty acids independent of obesity in normal

men. J Clin Endocrinol Metab. 2002; 87: 3023–28.

Sethi J, Hotamisligil G 1998; unpublished data.

Setter SM, Campbell RK, Cahoon C. Biochemical Pathway of Micro vascular

Complication in Diabetes Mellitus. Ann Pharmacother. 2003; 37: 1858-66.

Sfikakis PP, Grigoropoulos V, Emfietzoglou I, Theodossiadis G, Tentolouris

N, Delicha E, Katsiari C, Alexiadou K, Hatziagelaki E,Theodossiadis PG.

Infliximab for diabetic macular edema refractory to laser photocoagulation:

186

Bibliography

a randomized, double-blind, placebo-controlled, crossover, 32-week study.

Diabetes Care. 2010; 33(7):1523-8.

Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh

FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming

growth factor-beta1 correlates with long-term renoprotection in insulin-

dependent diabetic patients. American Journal of Kidney Diseases. 1999;

34:818-823.

Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse

effects for diabetic complications. JAMA. 2002; 288: 2579–2588.

Shimabukuro M. Role of nitric oxide in obesity-induced beta cell disease. J.

Clin. Invest. 1997100:290–295.

Shoelson SE, Lee J, and Yuan M. Inflammation and the IKK beta/I kappa

B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int. J.

Obes. Relat. Metab. Disord. 2003; 27(Suppl. 3):S49–S52.

Sica A, Wang JM, Colotta F, Dejana E, Mantovani A, Oppenheim JJ, Larsen CG,

Zachariae CO, Matsushima K. Monosyte chemotactic and activating factor

gene expression induced in endothelial cells by IL-1 and tumor necrosis

factor. J. Immunol. 1999; 144:3034-3038.

Singh R, Shaw J, Zimmet P. Epidemiology of childhood type 2 diabetes in the

developing world. Pediatr Diabetes. 2004; 5:154-168.

187

Bibliography

Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance

among children and adolescents with marked obesity. N Engl J Med. 2002;

346:802–10.

Sjoholm Ake, Thomas Nystrom. Inflammation and the etiology of type-2

diabetes. Diabetes Metab Res Rev. 2006; 22: 4–10

Smith CA, Farrah T, Goodwin RG the TNF receptor super family of cellular

and viral proteins: activation costimulation and death Cell.  1994; 76:959-

962.

Smith LL, Burnet SP, Mc Neil JD. Musculoskeletal manifestations of diabetes mellitus. Br J Sports Med. 2003; 37: 30-35.

Smith S, Lall AK. A study on serum lipid profile levels of diabetics and non-

diabetics among naini region of Allahabad, India. Turk J Biochem. 2008;

33(4): 138-141.

Soskolne WA, Klinger A. The relationship between periodontal diseases and

diabetes: An overview. Ann Periodontol. 2001; 6:91-98.

Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS BRL 49653

blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new

insulin-sensitizing mechanism for thiazolidinediones. Diabetes.  1998;

47: 691-695.

188

Bibliography

Sovza SC, Devargas LM, Yamamoto MT, Lien P, Franciosa MD, Moss LG,

Greenberg AS Over expression of perilipin A and B block the ability of tumor

necrosis factor alpha to increase lipolysis in 3T3-LI adipocytes. J Bio Chem.

1998; 273:24665-24669.

Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. IL-6

and TNF-alpha expression in, and release from, contracting human skeletal

muscle. Am J Physiol Endocrinol Metab. 2002; 283: 1272–1278.

Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall

G, Febbraio M, Pedersen BK. Acute interleukin-6 administration does not

impair muscle glucose uptake or whole-body glucose disposal in healthy

humans. J Physiol. 2003; 548: 631–638.

Stouthard JM, Oude Elferink RP, Sauerwein HP: Interleukin-6 enhances

glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Commun.

1996; 220:241-245,

Stumvoll Michael, Barry J Goldstein, Timon W van Haeften. Type 2 diabetes:

principles of pathogenesis and therapy Lancet.  2005, 365:1333-46.

Stumvoll Michael, Tataranni PA, Stefan N, Vozarova B, Bogardus C. Glucose

allostasis. Diabetes.  2003; 52: 903-09.

Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H. Advanced glycation

end products-cytokine-nitric oxide sequence pathway in the development

of diabetic nephropathy: Amino guanidine ameliorates the over expression

189

Bibliography

of tumour necrosis factor-alpha and inducible nitric oxide synthase in

diabetic rat glomerular. Diabetologia.  1999; 42:878–886.

Sundgren-Andersson AK, Ostlund P, Bartfai T: IL-6 is essential in TNF-alpha-

induced fever. Am J Physio.  1998; 275: R2028–R2034.

Suji G and Sivakami S. Glucose, glycation and ageing. Bio gerontology.  2004; 5: 365-373.

Temelkova KT, Henkel E, Koelher C. Subclinical inflammation in newly

detected type II diabetes and impaired glucose tolerance. Diabetologia. 

2002 ; 45-151

Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadia CS, Chrousos GP:

Dose-dependent effects of recombinant human interleukin-6 on glucose

regulation. J Clin Endocrinol Metab.  1997; 82:4167–4170.

Ueki, K, Kondo, T, and Kahn, C.R. Suppressor of cytokine signalling 1 (SOCS-

1) and SOCS-3 cause insulin resistance through inhibition of tyrosine

phosphorylation of insulin receptor substrate proteins by discrete

mechanisms.  2004.24:5434–5446.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-

glucose control with metformin on complications in overweight patients

with type 2 diabetes (UKPDS 34). Lancet.  1998; 352:854–65.

190

Bibliography

UKPDS Group. UK Prospective Diabetes Study 16: overview of six years’ therapy

of type 2 diabetes - a progressive disease. Diabetes.  1995; 44: 1249-58.

Unger RH. Lipotoxic diseases. Ann Rev Med.  2002; 53: 319-36.

Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor

necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in

genetic obesity. Endocrinology.  1998; 139:4832-4838.

Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from

obesity-induced insulin resistance in mice lacking TNF-alpha function.

Nature.  1997; 389:610-614.

Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P,

Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK: Interleukin-6

stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab.

2003; 88: 3005–3010.

Valdez R, Liu T, Yoon PW, Khoury MJ. Family history and prevalence of

diabetes in the U.S. population. Diabetes Care.  2007; 30:2517–22.

Ventre J, Doebber T, Wu M, Macnaul K, Stevens K, Pasparakis M, Kollias G,

Moller DE Targeted disruption of the tumor necrosis factor-alpha gene-

metabolic consequencesin obese and non-obese mice. Diabetes. 1997;

46:1526-1531.

Verma M, Paneri S, Badi P, Raman PG. Effect of increasing duration od diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivity. IJCB. 2006; 21(1): 142-146.

191

Bibliography

Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern

Med.  2002; 251: 87-101.

Wang TT, Wu XH, Zhang SL, Chan JSD. Effect of glucose on the expression of

the angiotensinogen gene in opossum kidney cells. Kidney International.

1998; 53: 312–319.

Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of

glycemia on all-cause and cardiovascular mortality. The San Antonio Heart

Study. Diabetes Care.  1998; 21:1167–72.

Wells L, Hart G: O-GlcNAc turns twenty: functional implications for

posttranslational modification of nuclear and cytosolic protein with a sugar.

FEBS Lett.  2003; 546:154–158.

Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K,

Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the

metabolic syndrome in children and adolescents. N Engl J Med. 2004;

350:2362–2374.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr.

Obesity is associated with macrophage accumulation in adipose tissue. J Clin

Invest.  2003; 112:1796 –1808.

192

Bibliography

Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin

secretory dysfunction and insulin resistance in the pathogenesis of type 2

diabetes mellitus. J Clin Invest.  1999; 104: 787–94.

Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals

with impaired fasting glucose and/or impaired glucose tolerance. Diabetes.

1999; 48: 2197–203.

Wilfried Dinh, Reiner Füth, Werner Nickl, Thomas Krahn, Peter Ellinghaus

Thomas Scheffold. Elevated plasma levels of TNF alpha and Interleukin-6 in

patients with diastolic dysfunction and glucose metabolism disorders,

Cardiovascular Diabetology.  2009, 8:58.

Wilson J, Balkwill F. Semin. Cancer Biol.  2002; 12(2), 113-120.

World health organization. Definition, diagnosis and classification of

diabetes mellitus and its complication .Report of a WHO consultation, WHO,

Geneva. 1999.

Xu H. Exclusive action of Tran’s membrane TNF alpha in adipose tissue

leads to reduced adipose mass and local but not systemic insulin resistance.

Endocrinology.  2002; 143:1502–1511.

Yach D, Hawkes C, Gouuld CL, Hofman KJ. The Global Burden of Chronic Diseases. Overcoming the impediments to prevention and

control. JAMA.  2004; 291: 2616-2622.

Yin MJ, Yamamoto, and Gaynor, R.B. 1998.The anti- inflammatory agent’s

aspirin and salicylate inhibit the activity of I (kappa) B kinase-beta. 1998;

396:77–80.

193

Bibliography

Yki-Jarvinen H. Glucose toxicity. Endocr Rev.  1992; 13: 415-31.

Yoshida S, Sotozono C, Ikeda T, Kinoshita SInterleukin−6 [IL−6] production

by cytokine−stimulated human Müller cells. Curr Eye Res.  2001; 22,341–

347.

Yu C. Mechanism by which fatty acids inhibit insulin activation of insulin

receptor substrate-1(IRS-1)-associated phosphatidylinositol 3-kinase

activity in muscle. J. Biol. Chem.   2002; 277:50230–50236.

Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesityand diet-induced

insulin resistance with salicylates or targeted disruption of Ikk beta. Science

2001, 293:1673–1677.

Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity,

stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis

2000; 148: 209.

Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacques-Silva MC,Canani LH,

Gross JL . Endothelin-1 levels and albuminuria in patients with type-2

diabetes mellitus. Diabetes Research and Clinical Practice 2008; 80:299-

304.

Zentella A, Manogue K, Cerami A.Cachetin/TNF-mediated lactate production

in cultured myocytes is linked to activation of futile substrate cycle.

Cytokine. 1993; 5:436-447.

194

Bibliography

Zheng L, Szab C and Kern TS. “Poly (ADP-ribose) polymerase is involved in

the development of diabetic retinopathy via regulation of nuclear factor-

κB,” Diabetes, 2004; 53: 2960–2967.

Zick, Y. Role of Ser/Thr kinases in the uncoupling of insulin signalling. Int. J.

Obes. Relat. Metab. Disord.  2003; 27(Suppl. 3):S56–S60.

Zimmet P, Alberti KG, Shaw J. Global and societal implications ofthe diabetes

epidemic. Nature. 2001; 414:782–87.

Zorena K, Mysliwska J, Myśliwiec M, Balcerska A, Raczyńska-Woźniak D,

Raczyńska K. Inflammatory and angiogenic factors in children with diabetic

retinopathy. Family Med. Prim. Care Rev. 2007; 4: 1007-1010.

Zorena K, Dorota Raczynska and Krystyna Raczynska. Immunological Risk

Factors for the Development and progression of Diabetic Retinopathy.

2012; ISBN: 978-953-51-0044-7.

195